FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912385100> ?p ?o ?g. }

• W2912385100 endingPage "214" @default.
• W2912385100 startingPage "214" @default.
• W2912385100 abstract "Shavit et al.1.Shavit L. Lifschitz M.D. Gabizon A. et al.Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment of ovarian cancer.Kidney Int. 2013; 85: 213Abstract Full Text Full Text PDF Scopus (9) Google Scholar and Demoulin and Jadoul2.Demoulin N. Jadoul M. Interferon-α-induced thrombotic microangiopathy in patients with chronic myelogenous leukemia.Kidney Int. 2013; 85: 213-214Abstract Full Text Full Text PDF Scopus (2) Google Scholar provide additional examples of chemotherapy-induced thrombotic microangiopathy (TMA). We thank these authors for reviewing the possible role of the above chemotherapeutic agents in the development of TMA. Both interferon-α3.Badid C. McGregor B. Faivre J.M. et al.Renal thrombotic microangiopathy induced by interferon-alpha.Nephrol Dial Transplant. 2001; 16: 846-848Crossref PubMed Scopus (22) Google Scholar and -β4.Broughton A. Cosyns J.P. Jadoul M. Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report.Clin Nephrol. 2011; 76: 396-400Crossref PubMed Scopus (24) Google Scholar,5.Olea T. Díaz-Mancebo R. Picazo M.L. et al.Thrombotic microangiopathy associated with use of interferon-beta.Int J Nephrol Renovasc Dis. 2012; 5: 97-100Crossref PubMed Google Scholar have been associated with TMA. However, the mechanism by which interferon-α and -β could induce TMA lesions remains unclear. Drugs such as interferon might disrupt complex pathways of complement regulation and have a role in endothelial damage.3.Badid C. McGregor B. Faivre J.M. et al.Renal thrombotic microangiopathy induced by interferon-alpha.Nephrol Dial Transplant. 2001; 16: 846-848Crossref PubMed Scopus (22) Google Scholar In recent years, mutations of complement system regulators have been directly implicated in the induction of atypical hemolytic uremic syndrome.6.Meri S. Complement activation in diseases presenting with thrombotic microangiopathy.Eur J Intern Med. 2013; 24: 496-502Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar It is possible that alteration of alternate pathway of the complement system might be involved in many such cases of chemotherapy-induced TMA. We thank Shavit and colleagues7.Kwa M. Baumgartner R. Shavit L. et al.Is renal thrombotic microangiopathy an emerging problem in the treatment of ovarian cancer recurrences?.Oncologist. 2012; 17: 1534-1540Crossref PubMed Scopus (18) Google Scholar to bring to our attention their previously reported case series on renal TMA seen following pegylated liposomal doxorubicin (PLD) use. While PLD was implicated as a cause of the renal TMA in the three cases reported by these authors,7.Kwa M. Baumgartner R. Shavit L. et al.Is renal thrombotic microangiopathy an emerging problem in the treatment of ovarian cancer recurrences?.Oncologist. 2012; 17: 1534-1540Crossref PubMed Scopus (18) Google Scholar two of the three patients had also received either bevacizumab or gemcitabine. Bevacizumab and gemcitabine, as noted in our review,8.Jhaveri K.D. Shah H.H. Calderon K. et al.Glomerular diseases seen with cancer and chemotherapy: a narrative review.Kidney Int. 2013; 84: 34-44Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar have also been associated with renal TMA. Nevertheless, anthracycline therapy is widely used in many cancer treatments and knowledge of both glomerular epithelial9.Mohamed N. Goldstein J. Schiff J. et al.Collapsing glomerulopathy following anthracycline therapy.Am J Kidney Dis. 2013; 61: 778-781Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar and endothelial damage7.Kwa M. Baumgartner R. Shavit L. et al.Is renal thrombotic microangiopathy an emerging problem in the treatment of ovarian cancer recurrences?.Oncologist. 2012; 17: 1534-1540Crossref PubMed Scopus (18) Google Scholar by such agents is useful to the onco-nephrologist. In addition, since the writing of our review,8.Jhaveri K.D. Shah H.H. Calderon K. et al.Glomerular diseases seen with cancer and chemotherapy: a narrative review.Kidney Int. 2013; 84: 34-44Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar other novel chemotherapeutic agents have also been associated with glomerular disease. Sasaki et al.10.Sasaki K. Anderson E. Shankland S. et al.Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor.Am J Kidney Dis. 2013; 61: 988-991Abstract Full Text Full Text PDF PubMed Scopus (18) Google Scholar report a case of diffuse proliferative immunoglobulin A–dominant immune complex glomerulonephritis in a patient who received cetuximab for recurrent oral squamous cell carcinoma. In this case, the authors make note of the rapid recovery of kidney function within 3 weeks of discontinuing the drug. This case suggests the need for monitoring kidney function in patients being treated with recently developed monoclonal antibodies. Finally, a recent letter to the editor suggested an association of lenolilomide (anti–multiple myeloma agent) with minimal change disease.11.Jamme M. Galichon P. Hertig A. Minimal change disease and lenalidomide.Am J Kidney Dis. 2013; (pii: S0272-6386): 01010-10101Google Scholar As the field of oncology is rapidly growing, both oncologists and nephrologists will need to be vigilant for any glomerular nephrotoxicities that might occur following the use of novel chemotherapeutic agents." @default.
• W2912385100 created "2019-02-21" @default.
• W2912385100 creator A5018399640 @default.
• W2912385100 creator A5084077044 @default.
• W2912385100 creator A5088037254 @default.
• W2912385100 date "2014-01-01" @default.
• W2912385100 modified "2023-10-17" @default.
• W2912385100 title "The Authors Reply:" @default.
• W2912385100 cites W1970476822 @default.
• W2912385100 cites W1976604088 @default.
• W2912385100 cites W1992281868 @default.
• W2912385100 cites W2005146857 @default.
• W2912385100 cites W2009700335 @default.
• W2912385100 cites W2021714582 @default.
• W2912385100 cites W2042961417 @default.
• W2912385100 cites W2064357278 @default.
• W2912385100 cites W2106587914 @default.
• W2912385100 cites W2142314174 @default.
• W2912385100 doi "https://doi.org/10.1038/ki.2013.411" @default.
• W2912385100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24380912" @default.
• W2912385100 hasPublicationYear "2014" @default.
• W2912385100 type Work @default.
• W2912385100 sameAs 2912385100 @default.
• W2912385100 citedByCount "2" @default.
• W2912385100 countsByYear W29123851002022 @default.
• W2912385100 crossrefType "journal-article" @default.
• W2912385100 hasAuthorship W2912385100A5018399640 @default.
• W2912385100 hasAuthorship W2912385100A5084077044 @default.
• W2912385100 hasAuthorship W2912385100A5088037254 @default.
• W2912385100 hasBestOaLocation W29123851001 @default.
• W2912385100 hasConcept C126322002 @default.
• W2912385100 hasConcept C134018914 @default.
• W2912385100 hasConcept C203014093 @default.
• W2912385100 hasConcept C2776178377 @default.
• W2912385100 hasConcept C2776513394 @default.
• W2912385100 hasConcept C2777878052 @default.
• W2912385100 hasConcept C2779134260 @default.
• W2912385100 hasConcept C2909179924 @default.
• W2912385100 hasConcept C555293320 @default.
• W2912385100 hasConcept C71924100 @default.
• W2912385100 hasConcept C90924648 @default.
• W2912385100 hasConceptScore W2912385100C126322002 @default.
• W2912385100 hasConceptScore W2912385100C134018914 @default.
• W2912385100 hasConceptScore W2912385100C203014093 @default.
• W2912385100 hasConceptScore W2912385100C2776178377 @default.
• W2912385100 hasConceptScore W2912385100C2776513394 @default.
• W2912385100 hasConceptScore W2912385100C2777878052 @default.
• W2912385100 hasConceptScore W2912385100C2779134260 @default.
• W2912385100 hasConceptScore W2912385100C2909179924 @default.
• W2912385100 hasConceptScore W2912385100C555293320 @default.
• W2912385100 hasConceptScore W2912385100C71924100 @default.
• W2912385100 hasConceptScore W2912385100C90924648 @default.
• W2912385100 hasIssue "1" @default.
• W2912385100 hasLocation W29123851001 @default.
• W2912385100 hasLocation W29123851002 @default.
• W2912385100 hasOpenAccess W2912385100 @default.
• W2912385100 hasPrimaryLocation W29123851001 @default.
• W2912385100 hasRelatedWork W2014735526 @default.
• W2912385100 hasRelatedWork W2018670987 @default.
• W2912385100 hasRelatedWork W2133766813 @default.
• W2912385100 hasRelatedWork W2169515258 @default.
• W2912385100 hasRelatedWork W2387692709 @default.
• W2912385100 hasRelatedWork W2398766250 @default.
• W2912385100 hasRelatedWork W2612022177 @default.
• W2912385100 hasRelatedWork W2887692055 @default.
• W2912385100 hasRelatedWork W4367174928 @default.
• W2912385100 hasRelatedWork W2491870392 @default.
• W2912385100 hasVolume "85" @default.
• W2912385100 isParatext "false" @default.
• W2912385100 isRetracted "false" @default.
• W2912385100 magId "2912385100" @default.
• W2912385100 workType "article" @default.